These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7863019)

  • 1. Do enzyme inducers modify haloperidol decanoate rate of release?
    Pupeschi G; Agenet C; Levron JC; Barges-Bertocchio MH
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1323-32. PubMed ID: 7863019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
    Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between carbamazepine and bromperidol.
    Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
    Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
    Pan L; Vander Stichele R; Rosseel MT; Berlo JA; De Schepper N; Belpaire FM
    Ther Drug Monit; 1999 Oct; 21(5):489-97. PubMed ID: 10519444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
    Ulrich S; Neuhof S; Braun V; Meyer FP
    Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data.
    Hirokane G; Someya T; Takahashi S; Morita S; Shimoda K
    Ther Drug Monit; 1999 Feb; 21(1):82-6. PubMed ID: 10051058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2-dopamine-receptor occupancy during treatment with haloperidol decanoate.
    Scherer J; Tatsch K; Albus M; Schwarz J; Mager T; Oertel WH
    Eur Arch Psychiatry Clin Neurosci; 1997; 247(2):104-6. PubMed ID: 9177957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
    Gelders YG
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
    Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels.
    Iwahashi K; Miyatake R; Suwaki H; Hosokawa K; Ichikawa Y
    Clin Neuropharmacol; 1995 Jun; 18(3):233-6. PubMed ID: 8635181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.